Back to top

Analyst Blog

Gilead Sciences, Inc. (GILD - Analyst Report) performed very well in the second quarter of 2013 driven by its strong product portfolio. The robust sales of newly launched products like Complera/Eviplera and Stribild are very encouraging.

Stribild has performed well since launch in the U.S. in Aug 2012. Sales of the drug climbed 8% sequentially to $99.4 million in the second quarter of 2013. The EU approval of the drug in May 2013 has boosted the sales potential of the drug. Sales of Complera/Eviplera, launched in 2011, climbed 27% sequentially to $188.7 million in the second quarter of 2013. We expect these products to continue performing well.

The product portfolio was further strengthened by the European approval of HIV drug cobicistat (150 mg version). The drug will be marketed in the EU under the trade name Tybost.

The drug acts as a “boosting” agent for the HIV protease inhibitors - such as Reyataz (atazanavir) and Prezista (darunavir) - enabling the HIV therapy to be dosed once daily.

The approval by the EC was based on positive data from a phase III study (114) which showed that cobicistat was non-inferior to AbbVie Inc.’s (ABBV - Analyst Report) HIV therapy Norvir (ritonavir)  over 48 weeks in treatment naïve HIV patients. Approval was also based on pharmacokinetic data which revealed that the addition of cobicistat boosted the exposure of HIV therapies Reyataz and Prezista similar to Norvir. We note that cobicistat is a component of the HIV combination pill Stribild.

Gilead expects 2013 product revenue in the range of $10–$10.2 billion, reflecting an increase of 6%–9% over 2012 levels. We expect Gilead to easily achieve the guidance driven by its strong product portfolio.

Gilead currently carries a Zacks Rank #3 (Hold).  However, stocks such as Roche (RHHBY - Analyst Report) and Eli Lilly and Company (LLY - Analyst Report) appear to be more attractive.  Roche carries a Zacks Rank #1 (Strong Buy) while Eli Lilly carries a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CENTURY ALU… CENX 22.53 +4.50%
ERBA DIAGNO… ERB 2.91 +4.30%
PLANAR SYST… PLNR 4.31 +3.86%
MALLINCKROD… MNK 72.17 +3.83%
GTT COMMUNI… GTT 12.06 +3.52%